Related Experiment Videos
Promising new agents in osteoporosis
J Y Reginster1, Y Henrotin, C Gosset
1WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, University of Liège, Belgium.
Abstract:
Currently marketed inhibitors of bone resorption or stimulators of bone formation have significantly contributed to a better preventive and therapeutic approach to postmenopausal and senile osteoporosis. However, none of the available compounds has unequivocally demonstrated an ability to fully prevent the occurrence of new vertebral or peripheral osteoporotic fractures once the disease is established. Therefore, several new medications are being developed, with the aim of providing a better risk-benefit profile and/or a more favourable cost-utility assessment than available drugs. Potential inhibitors of bone resorption include specific inhibitors of the osteoclast's proton pump, inhibitors of prostaglandins or nitric oxide donors. Stimulators of osteoblastic activity and subsequent bone formation might be obtained by strontium salts, peptides of the parathyroid hormone family, growth hormone and insulin-like growth factors or bone morphogenetic proteins. Most of these compounds are now undergoing phase II/III development programmes, and results evaluating their potential benefit should be available within 1 to 5 years.
Insights
New osteoporosis medications aim to improve fracture prevention beyond current treatments. Ongoing research focuses on novel bone resorption inhibitors and formation stimulators, with results expected within five years.
Area of Science:
- Orthopedics and Bone Biology
- Pharmacology and Drug Development
Background:
- Current osteoporosis treatments improve prevention and therapy but do not fully prevent fractures in established disease.
- Significant unmet need exists for osteoporosis medications with improved risk-benefit profiles and cost-utility.
Purpose of the Study:
- To review emerging pharmacological agents for osteoporosis treatment.
- To highlight novel inhibitors of bone resorption and stimulators of bone formation in development.
Main Methods:
- Review of current and pipeline osteoporosis therapeutics.
- Categorization of novel agents by mechanism of action (bone resorption inhibition vs. bone formation stimulation).
Main Results:
- Pipeline drugs include osteoclast proton pump inhibitors, prostaglandin inhibitors, and nitric oxide donors.
- Bone formation stimulators under investigation include strontium salts, parathyroid hormone peptides, growth hormone, insulin-like growth factors, and bone morphogenetic proteins.
- Many novel compounds are in Phase II/III development.
Conclusions:
- New osteoporosis drug development targets enhanced fracture prevention and improved therapeutic profiles.
- Clinical trial results for these promising agents are anticipated within 1-5 years.